Galmed Reports 3-4x Cell Death Boost for Aramchol Combo in Prostate Cancer
GLMD sits 27% above its 52-week low of $0.411 on light trading volume (0.1× avg).
Summary
Galmed announced preclinical results showing Aramchol plus enzalutamide kills 3-4x more prostate cancer cells than enzalutamide alone, with a patent filed and partnering talks planned.
Key Events · Product Development and Regulatory · GLMD
-
Preclinical Combo Data
Aramchol + enzalutamide showed 3-4 fold increase in cell death vs enzalutamide alone in VCaP prostate cancer cell line.
-
Patent Filed
Galmed recently submitted a patent application covering the Aramchol-enzalutamide combination.
-
Partnering Plans
Company intends to initiate discussions with potential partners based on the new data and patent.
-
Market Opportunity
Xtandi global sales were ~$8B (2024) and ~$6B (2025); composition patents expire 2026 EU / 2027 US, with US price cut scheduled 2027.
Analysis · GLMD · Life Sciences
Galmed disclosed first-time preclinical data showing Aramchol combined with enzalutamide (Xtandi) produced a 3-4 fold increase in cell death versus enzalutamide alone in a prostate cancer cell line. The company has filed a patent application for the combination and plans to initiate partnering discussions. This expands Aramchol's oncology opportunity into a multibillion-dollar market where Xtandi's composition patents expire in 2026-2027, potentially positioning the combination as a lifecycle management strategy.
At the time of this filing, GLMD was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.41 to $1.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.